At a glance
ClinicalIndex Comparison RecordN/ACompleted· 57 enrolled
Drug / intervention
Sunitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With Metastatic Renal Cell Carcinoma in Latin America
In Brief
An observational study evaluating Sunitinib for Metastatic Renal Cell Carcinoma ( mRCC). Completed, enrolled 57 participants across 7 sites in 4 countries.
Detailed Summary
To describe real-world demographic and clinical characteristics, treatment characteristics, and clinical outcomes among patients in Latin America who were treated with first-line sunitinib for metastatic renal cell carcinoma and switched from the 4/2 to 2/1 administration schedule
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma ( mRCC)
CountriesArgentina, Brazil, Colombia, Ecuador
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartDec 2019
Primary CompletionDec 2020
TodayJul 2026
First PostedOct 3, 2019
Enrollment StartDec 13, 2019
Primary CompletionDec 2, 2020
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 6.7 years ago
Interventions
Sunitinibdrug
Patients to receive Sunitinib as first line therapy for mRCC